Patents Issued in November 13, 2018
  • Methods and products for nucleic acid production and delivery
    Patent number: 10124042
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 13, 2018
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Mutant OPAA enzymes with increased catalytic efficiency on organophosphorus compound EA1356
    Patent number: 10124043
    Abstract: The invention comprises isolated, mutant, non-wild-type organophosphorus acid anhydrolase (OPAA) enzymes having three site mutations, methods of production, and methods of use to effectively degrade organophosphorus compound EA1356 (2-methylcyclohexyl methylphosphonofluoridate) with greater catalytic efficiency than the wild-type OPAA enzyme.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 13, 2018
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Steven P Harvey, Mark A Guelta, Leslie R McMahon
  • Use of photolyase for reducing or improving subclinical field cancerization associated with actinic keratosis
    Patent number: 10124044
    Abstract: The present invention relates to the use of photolyase enzymes to reduce or improve subclinical skin field cancerization associated with actinic keratosis or non-melanoma skin cancer (NMSC) and methods for the therapeutic treatment of subclinical field cancerization associated with actinic keratosis and/or non-melanoma skin cancer (NMSC).
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 13, 2018
    Assignees: ISDIN, S.A., HOSPITAL CLINIC BARCELONA, INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
    Inventors: Carlos Ramón Trullas Cabanas, Susana Puig I Sarda, Josep Malvehy Guilera
  • Methods and compositions for sustained immunotherapy
    Patent number: 10124045
    Abstract: This disclosure provides methods of making functionalized PEG iron oxide nanoparticles.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: November 13, 2018
    Assignee: UTI LIMITED PARTNERSHIP
    Inventor: Pedro Santamaria
  • HLA-DR-binding antigen peptide derived from WT1
    Patent number: 10124046
    Abstract: The present invention provides a method of treating or preventing cancer, by administering a peptide consisting of 16-25 contiguous amino acids in the amino acid sequence of human WT1 of SEQ ID NO: 1, which has the amino acid sequence of SEQ ID NO: 24, an expression vector having a polynucleotide encoding said peptide or a cell containing the expression vector to a subject in need thereof.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 13, 2018
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Method of modifying the immune response
    Patent number: 10124047
    Abstract: Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: November 13, 2018
    Assignee: KODE BIOTECH LIMITED
    Inventors: Stephen Micheal Henry, Caroline Ann Oliver
  • Adenovirus vectors
    Patent number: 10124048
    Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Oxford University Innovation Limited
    Inventors: Simon Draper, Arturo Reyes, Saranya Sridhar, Adrian Hill, Sarah Gilbert, Anna Goodman
  • Acinetobacter baumannii antigens and the uses thereof
    Patent number: 10124049
    Abstract: The present invention relates to an isolated polypeptide antigen of Acinetobacter baumannii, comprising at least an amino acid sequence selected from the group consisting of: (a) SEQ ID NOs: 1-5; (b) an amino acid sequence having at least 80% sequence identity to SEQ ID NOs: 1, 3, 4 or 5; (c) an amino acid sequence having at least 60% sequence identity to SEQ ID NO: 2; and (d) a fragment of the amino acid sequence according to (a) to (c); wherein the polypeptide having the amino acid sequence according to (b) to (d) has immunostimulatory activity. The universal polypeptide antigens of Acinetobacter baumannii can be used in the universal vaccine preparation. The corresponding antibodies can be used in the diagnostic and treatment of Acinetobacter baumannii.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 13, 2018
    Assignee: NATIONAL CHUNG HSING UNIVERSITY
    Inventor: Chiou-Ying Yang
  • Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
    Patent number: 10124050
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: November 13, 2018
    Assignee: Pfizer Inc.
    Inventors: Wendy Jo Watson, Luis Pascual Jodar Martin-Montalvo, Raul Enrique Isturiz, Ralf Rene Reinert
  • Meningococcus serogroup X conjugate
    Patent number: 10124051
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group in the capsular polysaccharide, to give an oxidized polysaccharide with an aldehyde group; and (b) coupling the oxidized polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: November 13, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • DNA vaccine against virus of Yellow Fever
    Patent number: 10124052
    Abstract: The present invention relates to vaccines of DNA that code for specific viral sequences. The DNA vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/YFE). Besides the wild p/YFE construct, sequence E was also fused with the sequence that codes for the human lysosome-associated membrane protein (h-LAMP), generating the construct (pL/YFE). The results of the invention are considered to be very promising, since both constructs can induce T-cell response against the same epitopes induced by the 17DD vaccine, and the pL/YFE construct can also induce a satisfactory concentration of neutralizing antibodies. The pL/YFE vector was inoculated in mice, before intracerebral challenge with the virus of yellow fever. Surprisingly, 100% of the mice immunized with pL/YFE survived the challenge.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: November 13, 2018
    Assignee: FUNDACAO OSWALDO CRUZ
    Inventors: Ernesto Torres de Azevedo Marques, Rafael Dhalia, Romulo Maciel Filho
  • Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
    Patent number: 10124053
    Abstract: Described here is a method to produce a chimeric protein having portions of yellow fever virus and dengue virus. A small portion of the yellow fever virus 17D vaccine strain envelope protein (or other related flavivirus) can be replaced by the corresponding portion from the dengue virus envelope protein. In some embodiments the chimeric protein may be used to create a treatment composition for DENV infection. In others, the chimeric protein may be used to create a vaccine that will induce broadly protective antibodies against dengue virus and reduce the induction of non-neutralizing antibodies that will cause enhancement.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: November 13, 2018
    Inventors: Sharon Isern, Scott F. Michael
  • Vaccine combination against multiple dengue virus serotypes and preparation and application thereof
    Patent number: 10124054
    Abstract: Provided is a vaccine combination against multiple dengue virus serotypes and preparation thereof. The vaccine combination includes a first vaccine and a second vaccine, wherein the first vaccine includes a live-attenuated dengue virus and a live-attenuated chimeric dengue virus, and the second vaccine includes a plurality type of recombinant flagellin and envelope domain III fusion proteins, wherein an envelope domain III of each type of the recombinant flagellin and envelope domain III fusion proteins is derived from a different dengue virus serotype. Also provided is a method of preventing or treating viral infection by multiple dengue virus serotypes in a subject using the vaccine combination, including the steps of administering the first and then the second vaccines at a time interval of about 1-5 weeks.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: November 13, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Hsiao-Han Lin, Meng-Ju Tsai, Guan-Cheng Lin
  • Zika virus RNA vaccines
    Patent number: 10124055
    Abstract: The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 13, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • Alkylated influenza vaccines
    Patent number: 10124056
    Abstract: The present invention provides, among other things, improved influenza vaccines based on hemagglutinins containing one or more alkylated cysteine residues. In particular, the present invention provides influenza vaccines containing hemagglutinins treated with an alkylating agent and methods of making the same. Inventive influenza vaccines provided by the present invention have a remarkable ability to retain potency as determined by Single Radial Immunodiffusion (SRID) assay upon storage.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: November 13, 2018
    Assignee: Sanofi Pasteur Inc.
    Inventors: Brooke S. Milner, Jonathan Haines, Steven L. Hauser, Janet Beebe Poli
  • Method of quickly producing antibodies against avian influenza and maintain antibody titer of duck
    Patent number: 10124057
    Abstract: The present invention provides a method for enabling ducklings to quickly produce anti-avian influenza antibodies and maintain antibody titer, including: step 1) the first immunization is performed on ducklings at the age of 5 to 15 days: each duckling is inoculated with an avian influenza inactivated antigen in an abdomen, and simultaneously intramuscularly or subcutaneously immunized with an avian influenza inactivated oil-emulsion vaccine. In the method, through the double effects of intraperitoneal inoculation with the inactivated antigen and intramuscular or subcutaneous injection with the inactivated oil-emulsion vaccine on the ducklings, the ducklings can quickly produce an immune response so as to quickly produce the anti-avian influenza antibodies; and the immune dead time of the ducklings immunized with the avian influenza inactivated vaccine can be effectively reduced by more than 7 days.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 13, 2018
    Inventors: Ruiai Chen, Aiguo Zhang, Yufu Liu, Jiahua Xu, Shuqiong Zhang, Wenke Huang, Daxing Wu, Shichang Liao
  • Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine
    Patent number: 10124058
    Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 13, 2018
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin
  • Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes
    Patent number: 10124059
    Abstract: The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 13, 2018
    Assignee: BIONOR IMMUNO AS
    Inventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Birger Sørensen, Karolina Lawitz
  • Compositions and methods to treat aids
    Patent number: 10124060
    Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 13, 2018
    Assignee: University of Massachusetts
    Inventors: Shan Lu, Shixia Wang
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10124061
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 13, 2018
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Methods of treating, inhibiting and/or preventing an auditory impairment
    Patent number: 10124062
    Abstract: The present invention provides methods of treating an auditory impairment associated with outer hair cells of the cochlea in a subject. The method may comprise administering to said subject an effective amount of a composition comprising, as an active agent, an oligonucleotide sequence having a portion of a mammalian telomere sequence so as to reduce the auditory impairment thereby treating the auditory impairment in the subject.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 13, 2018
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventor: O'neil W. Guthrie
  • Stable compositions containing thrombin and methods for preparation and use thereof
    Patent number: 10124063
    Abstract: Compositions comprising thrombin and collagen and methods of preparation thereof are disclosed herein. In one embodiment, a composition comprises thrombin and collagen in an aqueous buffer solution, wherein the buffer solution includes at least one of a first compound represented by Formula I: R1—C(O)—O?M+, wherein R1 is —CH3, —CH2CH2C(O)OH, or —CH2CH2C(O)O?M+, and wherein M+ is a monovalent ion; or a second compound represented by Formula II: R2—C(O)—O?M2+?O—C(O)—R2, wherein R2 is —CH3 or —CH2CH3, and wherein M2+ is a divalent ion. In one embodiment, the buffer solution includes sodium acetate, calcium propionate, and sorbitol.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 13, 2018
    Assignee: Orthovita, Inc.
    Inventor: Venkat R. Garigapati
  • Antimicrobial compositions of aminoglycosidic antibiotics and zinc ion chelators specifically formulated for enhanced inhibition of bacterial colonization and antibacterial efficacy
    Patent number: 10124064
    Abstract: Pharmaceutical compositions comprising an aminoglycosidic antibiotic and at least one zinc-chelating agent in a specified concentration, and methods of inhibiting bacterial colonization, biofilm formation and if treating bacterial infections utilizing the compositions are provided. Topical formulations suitable for wound care, and surface-applicable formulations suitable for medical, industrial and household disinfecting needs are also described.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 13, 2018
    Assignee: University of Cincinnati
    Inventors: Andrew B. Herr, Gary Young
  • Lipids and lipid compositions for the delivery of active agents
    Patent number: 10124065
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: November 13, 2018
    Assignee: Novartis AG
    Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
  • Stabilized vancomycin formulations
    Patent number: 10124066
    Abstract: In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 13, 2018
    Assignee: INSMED INCORPORATED
    Inventors: Walter Perkins, Vladimir Malinin
  • CHG-compatible composition and method
    Patent number: 10124067
    Abstract: A composition for soothing irritation that does not diminish the efficacy of a topical antiseptic is disclosed. The composition comprises an emollient, an emulsifier, and a film-forming agent. Also, a method of soothing irritation without diminishing the efficacy of a topical antiseptic product comprises the steps of providing the topical antiseptic product comprising a cationic antiseptic agent, providing the composition, applying the topical antiseptic product to a target area on skin of a patient to coat the target area with the cationic antiseptic agent, and applying the composition to the coated target area.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: November 13, 2018
    Assignee: Sage Products, LLC
    Inventors: Jodi M. Balbinot, Arthur C. W. Georgalas
  • Hemostatic microspheres
    Patent number: 10124068
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 13, 2018
    Assignee: Baxter International, Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Peptidomimetic compounds and antibody-drug conjugates thereof
    Patent number: 10124069
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: November 13, 2018
    Assignee: Genentech, Inc.
    Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
  • Anti-HER2 antibody-maytansine conjugates and methods of use thereof
    Patent number: 10124070
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • ST-246 liquid formulations and methods
    Patent number: 10124071
    Abstract: The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 13, 2018
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A. C. L. S. Anderson, William Weimers, Gopi Krishna Kasi, N K Peter Samuel, Tove C. Bolken, Dennis E. Hruby
  • In-vivo reactive species imaging
    Patent number: 10124072
    Abstract: The disclosure features methods that include: administering to a subject a composition that includes particles, where each one of the particles features at least one targeting group that binds to a structural entity in the subject and at least one reacting group that reacts chemically with a reactive oxygen species in the subject, and where the particle emits luminescence when the reaction occurs; detecting the luminescence emission from the particles; and displaying an image of the subject showing locations of at least some reactive oxygen species in the subject based on the detected luminescence.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 13, 2018
    Inventors: Sunetra Ray, Daniel Ansaldi, Rajendra Singh
  • Targeting peptides and methods of use
    Patent number: 10124073
    Abstract: A compound includes at least one targeting peptide coupled to a detectable moiety. The targeting peptide binds to EDB-FN or EDA-FN and includes at least one of amino acid sequence selected from the group consisting of SEQ ID NOs: 1-30.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: November 13, 2018
    Assignee: Case Western Reserve University
    Inventors: Zheng-Rong Lu, Zheng Han, Hui Zhu
  • Indirect chromoendoscopy with an oral indigo carmine base preparation
    Patent number: 10124074
    Abstract: Indirect chromoendoscopy is performed by providing a subject with an orally administered composition which includes indigo carmine dye mixed with polyethylene glycol (PEG). Preferably, the subject ingests at least 160 mg of indigo carmine prior to the endoscopic procedure. This is accomplished by ingesting 1 ml to 6 L of a premixed or reconstituted indigo carmine and PEG composition up to twenty four hours prior to the endoscopic procedure.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: November 13, 2018
    Inventor: Toufic Kachaamy
  • Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
    Patent number: 10124075
    Abstract: A bionanofluid includes a carbon-based nanomaterial substantially mono-dispersed in a fluid. The carbon-based nanomaterial is surface modified with a polar group when the fluid is polar or with a non-polar group when the fluid is non-polar, and functionalized with a biological targeting moiety to allow specific association of the carbon-based nanomaterial to a targeted entity. A hybrid bionanofluid includes the bionanofluid, with the carbon-based nanomaterial further modified with a hybrid nanoparticle which includes an alloy, transition metal, semi-conductor, semi-metal or polymer based nanoparticle with biological targeting moiety. A hydrogel, foam, cream, spray or dried product includes the bionanofluid or hybrid bionanofluid. The bionanofluid or hybrid bionanofluid are useful in multimodal imaging (photo-luminescence, luminescence, photo-acoustic, MRI, ultrasound) and/or cellular targeting.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: November 13, 2018
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MC GILL UNIVERSITY
    Inventors: Mark Trifiro, Miltiadis Paliouras, Philip Roche, Idit Dotan, Lenore Beitel, Carlos Alvarado, Matthew Carnevale, Elliot Jonathan Mitmaker
  • Imaging agents and methods of use thereof
    Patent number: 10124076
    Abstract: Compositions and methods useful in connection with magnetic resonance imaging are provided. Metabolites hyperpolarized by dynanic nuclear polarization are used as reporter molecules in nuclear magnetic resonance (“NMR”) spectroscopy to study metabolic pathways and diagnose disease states. The reporter molecules include hyperpolarized glutamine and hyperpolarized acetate. The invention includes the reporter molecules, compositions including the reporter molecules in pharmaceutically acceptable carriers, methods for studying metabolic pathways that include introducing one or more of the reporter molecules to a mammalian subject and imaging a target substance using NMR spectroscopy, and kits useful in studying metabolic pathways that incorporate one or more of the reporter molecules and instructions for their use.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 13, 2018
    Assignee: HUNTINGTON MEDICAL RESEARCH INSTITUTES
    Inventors: Brian D. Ross, Pratip Bhattacharya
  • Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
    Patent number: 10124077
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 13, 2018
    Assignee: The General Hospital Corporation
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Lipid-based nanoparticles
    Patent number: 10124078
    Abstract: Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-? plaque deposits characteristic of Alzheimer's Disease.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: November 13, 2018
    Inventors: Ananth V. Annapragada, Jason L. Eriksen, Eric A. Tanifum, Indrani Dasgupta, Stephen C. Cook
  • Imaging of metastatic or recurrent cancer
    Patent number: 10124079
    Abstract: The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: November 13, 2018
    Assignee: Blue Earth Diagnostics Limited
    Inventors: Matthew Miller, David Gauden, David Schuster, Stefano Fanti, Cristina Nanni, Lucia Zanoni, Frode Willoch, Trond Velde Bogsrud, Tore Bach-Gansmo, Alessandra Musto
  • Hand disinfection device having a plasma and aerosol generator
    Patent number: 10124080
    Abstract: The invention relates to a disinfection device (1) for plasma disinfection of surfaces comprising a plasma generator (2) for generating a disinfecting plasma gas stream (PA), and comprising an at least partially closed disinfection area (5) that is in communicating connection with the plasma generator (2), which is configured for receiving the surface (6) to be disinfected. The disinfection device (1) has an aerosol generator (9) for generating an aqueous aerosol stream (A) containing particles. The aerosol generator (9) is in communicating connection with the plasma generator (2) in order to guide the plasma gas stream (PA) mixed with the aerosol stream (A) in the disinfection area (5) onto the surface (6) to be disinfected.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 13, 2018
    Assignee: Leibniz-Institut fuer Plasmaforschung und Technologie e.V.
    Inventors: Klaus-Dieter Weltmann, Manfred Stieber, Thomas Von Woedtke, Wilfried Kroemker
  • Ultraviolet illuminator
    Patent number: 10124081
    Abstract: A solution for disinfecting an area using ultraviolet radiation is provided. The solution can include an enclosure including at least one ultraviolet transparent window and a set of ultraviolet radiation sources located adjacent to the at least one ultraviolet transparent window. The set of ultraviolet radiation sources can be configured to generate ultraviolet radiation directed through the at least one ultraviolet transparent window. An input unit can be located on the enclosure and configured to generate an electrical signal in response to pressure applied to the enclosure. A control unit can be configured to manage the ultraviolet radiation by monitoring the electrical signal generated by the input unit and controlling, based on the monitoring, the ultraviolet radiation generated by the set of ultraviolet radiation sources.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: November 13, 2018
    Assignee: Sensor Electronic Technology, Inc.
    Inventors: Igor Agafonov, Alexander Dobrinsky, Michael Shur, Remigijus Gaska, Saulius Smetona
  • Fragrance delivery device, system, and method
    Patent number: 10124082
    Abstract: A fragrance delivery device, system and method is provided, comprising a housing including a rupture device and an absorbent member receivable in the housing. The system further includes a cartridge insertable within the housing and containing a fragrance medium therein. The rupture device of the housing is engageable with the cartridge to release the fragrance medium from the cartridge into the housing. The absorbent member absorbs the fragrance medium and permeates a fragrance from the fragrance medium to an external environment.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 13, 2018
    Assignee: TAKASAGO INTERNATIONAL CORPORATION (USA)
    Inventors: Thomas F. Santini, Anthony R. Budraitis
  • Sanitizer with an ion generator and ion electrode assembly
    Patent number: 10124083
    Abstract: A sanitizer with an ion generator and ion electrode assembly are provided. The ion generator is configured to generate ions using an AC voltage and an ion electrode assembly. The ion electrode assembly includes at least one emitter unit adapted for attachment to the ion generator. At least one ion source is attached to the at least one emitter unit for emitting ions. An emitter cover that is flexible has a thickness and extends from a proximal end to a distal end and defines an inner surface and encloses the at least one emitter unit for protecting the at least one ion source and the at least one emitter unit. The inner surface of the emitter cover is in a spaced relationship with the at least one ion source to define an air gap.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: November 13, 2018
    Assignee: DM Tec, LLC
    Inventor: Michael E. Robert
  • Ready to use biodegradable and biocompatible device and a method of preparation thereof
    Patent number: 10124084
    Abstract: The invention provides a ready to use biodegradable and biocompatible device and a method for manufacturing thereof. The device of present invention is a novel porous scaffold which can be used as carrier of plurality of therapeutics to quickly stop bleeding and other biomaterial and biomedical application. The scaffold can be directly applied to the spot of the wound and will stop bleeding within no time. The scaffold of the present invention comprises of combined application of air dry and freeze dry method. The scaffold also comprises of excellent ventilations properties and easy removal of the scaffold without causing any extra hemorrhage to the wound.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: November 13, 2018
    Assignee: Datt Life Sciences Private Limited
    Inventors: Rajan Datt, Ramadhar Kumar, Pallavi Shrivastava
  • Antimicrobial and antiviral hygienic products
    Patent number: 10124085
    Abstract: The present invention relates to hygienic products such as sanitary pads and tampons, patient/adult diapers and baby diapers which are made antimicrobial. In the present invention, a mixture of glucopon, chlorhexidine gluconate and triclosan is obtained from the boron compounds called sodium borate, zinc borate, sodium perborate tetrahydrate, borax pentahydrate and disodium octaborate tetrahydrate; and this mixture provides antifungal, anticandidal, antibacterial and antiviral properties to the woven or non-woven textile products and hygienic products. Additionally, the said hygienic products are made hydrophilic by means of the invention.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: November 13, 2018
    Assignee: YEDITEPE UNIVERSITESI
    Inventors: Fikrettin Sahin, Zeynep Ustaoglu, Selami Demirci, Okan Demir, Ayla Burcin Asutay
  • Composition, molded article, thread, medical kit and medical product with improved degradation profile
    Patent number: 10124086
    Abstract: A composition includes polydioxanone and/or a copolymer thereof and at least one carboxylic salt. A molding includes the composition. A thread includes the composition. A medical kit includes the composition and a medical product includes the composition.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: November 13, 2018
    Assignee: ITV Denkendorf Produktservice GmbH
    Inventors: Sven Oberhoffner, Erhard Müller
  • Detachable coupling for catheter
    Patent number: 10124087
    Abstract: A microcatheter comprising an elongate flexible tubular body, a tip body and a coupling is disclosed. The elongate flexible tubular body has a proximal end, a distal end and at least one lumen extending axially therethrough. The tip body has a proximal end and a distal end and a lumen extending axially therethrough. The coupling covers a portion of both the tubular body and tip body and is made from a first material and a second material, where the first material is different from the second material. The first material is compatible with an outermost layer of the tubular body and an outermost layer of the tip body, and the second material is configured to form a detachable bond with at least one of the tubular body and the tip body.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: November 13, 2018
    Assignee: COVIDIEN LP
    Inventor: Praveen De Silva
  • Lubricious medical device elements
    Patent number: 10124088
    Abstract: Embodiments of the invention include medical device elements formed from polymers with lubricious properties. In an embodiment, a method of forming a medical device element is included. The method can include mixing a first polymeric component and a second polymeric component to form a polymer mixture. The method can further include forming the polymer mixture into the medical device element. The method can also include treating the polymer mixture with at least one of an acid or a base. In an embodiment, a medical device is included. The medical device can include a lubricious element, the lubricious element comprising a mixture of a first polymeric component and a second polymeric component. The second polymeric component can include a polymer that is treated with at least one of an acid or a base after formation of the element. Other embodiments are also included herein.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: November 13, 2018
    Assignee: Surmodics, Inc.
    Inventors: Ralph A. Chappa, Nathan A. Lockwood, Joseph Schmidt McGonigle
  • Method of making biomedical patches with spatially arranged fibers
    Patent number: 10124089
    Abstract: A system and methods for producing a structure including a plurality of fibers is provided. The system includes a polymer collector having a predefined pattern, wherein the collector is charged at a first polarity, and a spinneret configured to dispense a polymer, wherein the spinneret is charged at a second polarity substantially opposite the first polarity such that polymer dispensed from the spinneret forms a plurality of fibers on the predefined pattern of the fiber collector.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 13, 2018
    Assignee: Washington University
    Inventor: Matthew R. MacEwan
  • Embolic devices
    Patent number: 10124090
    Abstract: Described herein are apparatus, compositions, systems and methods for occluding vascular structures and vascular malformations with radiopaque hydrogel filaments. The filaments can contain no support members and can be CT and MR compatible. Methods of forming such filaments are also disclosed.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: November 13, 2018
    Assignee: Terumo Corporation
    Inventors: Michael Constant, Edward Michael Keeley, Joshua Garretson, Gregory M. Cruise, Wendy Graczyk
  • Radioactive monolayer surface coating
    Patent number: 10124091
    Abstract: Disclosed are compositions including a film enriched with a radioisotope relative to its natural abundance, wherein the film has a thickness of one to ten atomic or molecular layers, decay of the radioisotope comprises emission of electrons, and a majority of the emitted electrons have an energy less than or equal to 700 electron volts (ev). Also disclosed are methods for making the compositions. The compositions can be used in microarrays, nanoarrays, microparticles, nanoparticles, power sources, sensing devices, and medical devices; they may also be used in a method of delivering low-energy electrons to a liquid, solid, molecular layer, or cell.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 13, 2018
    Assignee: Trustees of Tufts College
    Inventors: Charles Sykes, Alex Pronschinske, Colin Murphy